Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

OptimizeRx (OPRX) Retained Earnings: 2010-2024

Historic Retained Earnings for OptimizeRx (OPRX) over the last 15 years, with FY2024 value amounting to -$84.4 million.

  • OptimizeRx's Retained Earnings rose 4.03% to -$84.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$84.3 million, marking a year-over-year increase of 4.03%. This contributed to the annual value of -$84.4 million for FY2024, which is 3129.57% down from last year.
  • OptimizeRx's Retained Earnings amounted to -$84.4 million in FY2024, which was down 3129.57% from -$64.3 million recorded in FY2023.
  • In the past 5 years, OptimizeRx's Retained Earnings registered a high of -$35.3 million during FY2021, and its lowest value of -$84.4 million during FY2024.
  • For the 5-year period, OptimizeRx's Retained Earnings averaged around -$53.2 million, with its median value being -$46.7 million (2022).
  • Per our database at Business Quant, OptimizeRx's Retained Earnings soared by 106.11% in 2021 and then plummeted by 3762.07% in 2023.
  • Annual analysis of 5 years shows OptimizeRx's Retained Earnings stood at -$35.6 million in 2020, then grew by 1.06% to -$35.3 million in 2021, then plummeted by 32.45% to -$46.7 million in 2022, then plummeted by 37.62% to -$64.3 million in 2023, then plummeted by 31.3% to -$84.4 million in 2024.
  • Its Retained Earnings was -$84.4 million in FY2024, compared to -$64.3 million in FY2023 and -$46.7 million in FY2022.